Escient Pharmaceuticals, Inc.

23 articles about Escient Pharmaceuticals, Inc.

• Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders

  6/20/2023

  Escient Pharmaceuticals, a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-inflammatory disorders, announced positive results from a Phase 1 first-in-human study of EP262, a potent, highly selective small molecule antagonist of MRGPRX2.

• Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in Inhibition of Mast Cell Degranulation in Multiple Species at the European Academy of Allergy and Clinical Immunology

  6/8/2023

  Escient Pharmaceuticals today announced the presentation of preclinical data in multiple models of mast cell degranulation related to the company’s EP262 development program at the European Academy of Allergy and Clinical Immunology annual meeting being held in Hamburg, Germany, June 9-11, 2023.

• Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in a Mouse Model of Atopic Dermatitis at the American Academy of Dermatology Annual Meeting

  3/16/2023

  Escient Pharmaceuticals announced the presentation of preclinical data in a mouse model of atopic dermatitis related to the company’s EP262 development program at the American Academy of Dermatology annual meeting being held in New Orleans, Louisiana, March 17-21, 2023.

• Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Pharmacology of EP262 at the American Academy of Allergy, Asthma and Immunology Annual Meeting

  2/26/2023

  Escient Pharmaceuticals announced the presentation of preclinical data related to the company’s EP262 development program at the American Academy of Allergy, Asthma and Immunology Annual meeting being held in San Antonio, TX, February 24-27, 2023.

• Escient Pharmaceuticals Announces IND Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders

  1/30/2023

  Escient Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for EP262, enabling the initiation of a Phase 1 first-in-human study for the company’s second drug candidate to be advanced into clinical development.

• Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Development of EP262 at the 6th GA2LEN Global Urticaria Forum

  12/7/2022

  Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the presentation of preclinical data related to the company’s EP262 development program at the 6th GA2LEN Global Urticaria Forum being held in Berlin, Germany, December 7-8, 2022.

• Escient Pharmaceuticals Announces $120 Million Series C Financing

  11/28/2022

  Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, announced the closing of a $120 million Series C financing.

• Escient Pharmaceuticals Initiates Phase 2 PACIFIC Study Evaluating EP547, An Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus

  11/17/2022

  Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the initiation of a Phase 2 clinical study of EP547 in subjects with cholestatic pruritus.

• Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires

  11/16/2022

  Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the addition of three key new members to its leadership team.

• Escient Pharmaceuticals Appoints Joshua Grass, MBA as CEO

  1/5/2022

  Escient Pharmaceuticals today announced the appointment of Joshua Grass, MBA as Chief Executive Officer effective immediately.

• 

  4 Companies Ringing in New Year with New CEOs

  1/5/2022

  Several biopharma companies have adjusted their leadership teams to include new chief executive officers who are expected to guide the companies and their programs into the future.

• Escient Pharmaceuticals Announces Data Presentations Highlighting the Preclinical and Clinical Development of EP547 at AASLD The Liver Meeting® Digital Experience 2021

  11/4/2021

  Escient Pharmaceuticals Announces Data Presentations Highlighting the Preclinical and Clinical Development of EP547 at AASLD The Liver Meeting ® Digital Experience 2021

• Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP547, an MrgprX4-Targeted Oral Therapy for Cholestatic and Uremic Pruritus

  7/14/2021

  Escient Pharmaceuticals today announced positive results from a Phase 1 study of EP547, a new chemical entity and potent MrgprX4 antagonist, being developed for the treatment of pruritus associated with cholestasis and uremia.

• 

  BioSpace Movers & Shakers, May 28

  5/28/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Escient Pharmaceuticals Names Eric Deng, Ph.D., M.B.A. as Vice President, CMC Operations

  5/27/2021

  Escient Pharmaceuticals, Inc. , a clinical-stage, industry-leading platform company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications, today announced that Eric Deng, Ph.D., M.B.A., has joined the company as Vice President, Chemistry, Manufacturing and Controls (CMC) Operations.

• 

  BioSpace Movers & Shakers, May 21

  5/21/2021

  Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.

• Escient Pharmaceuticals Appoints Christian Weyer, M.D., M.A.S., as President and Chief Medical Officer

  5/17/2021

  Escient Pharmaceuticals, Inc. , a clinical-stage, industry-leading platform company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications, today announced that Christian Weyer, M.D., M.A.S., has joined the company as President and Chief Medical Officer.

• 

  BioSpace Movers & Shakers, May 7

  5/7/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Escient Pharmaceuticals Names Svetlana Makhni as Chief Financial Officer

  5/3/2021

  Escient Pharmaceuticals, Inc., a clinical-stage, industry-leading platform company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications, today announced the appointment of Svetlana Makhni as Chief Financial Officer effective May 3, 2021

• Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1/1b Clinical Trial of EP547, a MRGPR-targeted Therapy to Treat Cholestatic and Uremic Pruritus

  9/14/2020

  Sept. 14, 2020 13:00 UTC -- Proceeds support clinical development for lead program in cholestatic and uremic pruritus and second program for mast cell-related diseases -- Financing round led by Sanofi Ventures and Cowen Healthcare Investments and included new investors Redmile Group and Perceptive Advisors -- Jason Hafler, Ph.D., of Sanofi Ventures and Kevin Raidy of Cowen Healthcare Investments join Escient board of directors SAN DIEGO--( BUSINESS WIRE )-- Es